Updated results of HERA study: Extending trastuzumab for 2 years does not improve outcomes versus 1-year treatment
Findings confirm the current standard duration of adjuvant trastuzumab for women with HER2-positive early breast cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Findings confirm the current standard duration of adjuvant trastuzumab for women with HER2-positive early breast cancer
COMPARZ, INTORSECT & INTORACT - Three phase III studies investigating treatments of renal cell carcinoma reported at ESMO 2012
Results of the randomized BEBYP study
The increase in our knowledge and understanding of molecular pathways is leading to the identification of novel and appealing targets in oncology
New findings pose a question on optimal duration of trastuzumab therapy for women with HER2-positive early breast cancer; the subset analysis may give an answer
Comparing two bevacizumab-containing regimens as first-line therapy for HER2 negative metastatic breast cancer
An educational session explored a range of options that clinicians could adopt to manage cancer patients where the primary tumour site is unknown.
Find the most common oncology abbreviations.
Comprehensive guidelines for early and advanced BC management plus prevention and screening for BRCA mutation carriers
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.